APOPTOSIS AND BCL-2 EXPRESSION IN PROSTATE CANCER:
- 1 June 2001
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 165, 2126-2130
- https://doi.org/10.1097/00005392-200106000-00082
Abstract
Radiation induced apoptosis of prostate cancer cells may have therapeutic and prognostic significance in patients treated with radiotherapy. We determined whether the ability of prostate tumor cells to undergo apoptosis has potential value for predicting the clinical response of patients with prostate cancer to brachytherapy. A total of 76 patients with clinical stages T1 to 2 disease who were not receiving adjuvant therapy underwent transperineal implantation with 125iodine or 103palladium seeds and biopsy 7 to 23 months (median 12) after therapy. Nonresponders were classified using the American Society for Therapeutic Radiology and Oncology criteria. The apoptotic index was analyzed using the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labeling assay in archived biopsy specimens from 76 treated and 19 matched pretreatment control patients. Serial sections of prostatic tumors were also evaluated for the expression of bax and bcl-2 proteins (apoptosis regulators) by immunohistochemical testing. A significant increase in the apoptotic index was detected in post-brachytherapy compared with pretreatment prostate specimens (3.1% versus 2%, p <0.05), as well as in patients with negative biopsy at followup compared with those with persistent malignancy (3.4% versus 1.8%, p = 0.02). In addition, there was a significant elevation in bcl-2 expression in prostatic tissue in patients with treatment failure compared with responders (30.5% versus 13.1%, p <0.05). To our knowledge this is the first study to establish a correlation of apoptosis induction and bcl-2 over expression with treatment outcome in patients with prostate cancer after brachytherapy. Our findings have significant clinical implications for identifying the value of the apoptotic index and bcl-2 expression in prostatic tumors for predicting the therapeutic response to brachytherapy.Keywords
This publication has 23 references indexed in Scilit:
- Complications after prostate brachytherapy in the Medicare populationUrology, 2000
- RETROSPECTIVE COMPARISON OF RADICAL RETROPUBIC PROSTATECTOMY AND 125 IODINE BRACHYTHERAPY FOR LOCALIZED PROSTATE CANCERJournal of Urology, 1999
- Comparison of the 5-Year Outcome and Morbidity of Three-Dimensional Conformal Radiotherapy Versus Transperineal Permanent Iodine-125 Implantation for Early-Stage Prostatic CancerJournal of Clinical Oncology, 1999
- Biochemical Outcome After Radical Prostatectomy, External Beam Radiation Therapy, or Interstitial Radiation Therapy for Clinically Localized Prostate CancerJAMA, 1998
- Transient tyrosine phosphorylation of p34cdc2 is an early event in radiation-induced apoptosis of prostate cancer cellsThe Prostate, 1997
- Interstitial iodine-125 radiation without adjuvant therapy in the treatment of clinically localized prostate carcinomaCancer, 1997
- Apoptosis and clonogenic cell death in PC3 human prostate cancer cells after treatment with gamma radiation and suramin.Radiation Research, 1997
- Combination of Prostate-Specific Antigen, Clinical Stage, and Gleason Score to Predict Pathological Stage of Localized Prostate CancerJAMA, 1997
- Low risk of urinary incontinence following prostate brachytherapy in patients with a prior transurethral prostate resectionInternational Journal of Radiation Oncology*Biology*Physics, 1997
- bcl-2 over-expression delays radiation-induced apoptosis without affecting the clonogenic survival of human prostate cancer cellsInternational Journal of Cancer, 1997